Edoxaban: a new oral direct factor xa inhibitor.

@article{Camm2011EdoxabanAN,
  title={Edoxaban: a new oral direct factor xa inhibitor.},
  author={Aj. Camm and Henri Bounameaux},
  journal={Drugs},
  year={2011},
  volume={71 12},
  pages={
          1503-26
        }
}
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in the coagulation cascade. Edoxaban is a competitive inhibitor of factor Xa and has >10 000-fold greater… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 52 CITATIONS, ESTIMATED 35% COVERAGE

Novel antithrombotic agents for atrial fibrillation.

VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Oral anticoagulation with edoxaban.

  • Hamostaseologie
  • 2012
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Pharmacology of the new target-specific oral anticoagulants

  • Journal of Thrombosis and Thrombolysis
  • 2013
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives

  • European heart journal supplements : journal of the European Society of Cardiology
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 5 Highly Influenced Citations

Similar Papers

Loading similar papers…